Calamos Advisors LLC Summit Therapeutics Inc. Transaction History
Calamos Advisors LLC
- $15.7 Billion
- Q1 2025
A detailed history of Calamos Advisors LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 23,977 shares of SMMT stock, worth $562,979. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,977
Previous 23,821
0.65%
Holding current value
$562,979
Previous $425,000
8.71%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.2MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$573 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$274 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$185 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$154 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$132 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.72B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...